search
Back to results

Effects of Exercise on Cognitive Performance of Patients With Alzheimer-type Dementia. Pilot Study. (EFA-P)

Primary Purpose

Alzheimer Disease

Status
Unknown status
Phase
Not Applicable
Locations
Spain
Study Type
Interventional
Intervention
High intensity aerobic exercise+strength
Low intensity aerobic exercise+strength
Sponsored by
Basque Health Service
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Alzheimer Disease focused on measuring Alzheimer disease, exercise, cognition

Eligibility Criteria

55 Years - 85 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Subjects aged between 55 and 85 who meet, at the time of entry into the study, clinical criteria compatible with probable AD according to the criteria of the National Institute on Aging and the Alzheimer's Association, under mild or DCL-Alzheimers (Folstein MMSE> 19/20, GDS 3-4), diagnosis will be performed by specialist neurologists according to standard practice. Patients should be able to perform physical activity on a cycle ergometer or treadmill and also must exist a caregiver who agrees to accompany him to the physical exercise sessions.

-

Exclusion Criteria: Central nervous system disease history with the possibility of neuropsychological impairment (stroke, epilepsy, meningitis, severe head trauma). History of alcohol and drug abuse. Hachinski Ischemic Scale ≥ 7. Major depression diagnosed(CIE-10). History of severe psychiatric disease. Predictable changes in medication that may affect cognitive performance. Visual or auditory perceptual disorders that limit neuropsychological assessment. Unstable heart disease, severe behavioral problems that make impossible the intervention, or any condition judged by the investigator that advises against the intervention. -

Sites / Locations

  • Galdakao Hospital/Galdakao C.S.Recruiting
  • Basauri C.S.Recruiting
  • Hospital Universitario de Basurto

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

High intensity aerobic exercise+strength

Low intensity aerobic exercise+strength

Arm Description

The program consist in a "Continuous High aerobic exercise and moderate intensity intervals" (ShoshanaB et al, 2012) combined with "muscular strength exercises and joint mobility". Patients come three times a week for six months to the primary health center. A fitness expert nurse is responsible for monitoring the performance and adapt to the physical condition of the patient.Each exercise session consists of warming up time period, period of work and back to calm. Exercise intensity during the work period increases progressively as the program progresses. Aerobic exercise is performed on a cycle ergometer or treadmill.Muscle strength exercises and joint mobility are performed with dumbbells and ankle weights adapted to each patient.

The control group performed an exercise program similar to intervention but at low intensity that is below 35 or 40% of heart rate reserve (HRR).

Outcomes

Primary Outcome Measures

Change in cognitive performance that is measured in a blinded way with the cognitive section of the ADAS scale (Alzheimer's Disease Assessment Scale) at 0, 6 and 12
Cognitive performance is measured in a blinded way with the cognitive section of the ADAS scale (Alzheimer's Disease Assessment Scale) at 0, 6 and 12. ADAS is an instrument designed to assess the severity of cognitive disorders (ADAS-Cog) and noncognitive (ADAS-cog) in patients with Alzheimer-type dementia (ATD). The ADAS-Cog, that we use, consists of 11 items that assess mainly memory (3 items, 27 points), orientation (1 item, 8 points), language (5 items, 25 points) and praxis (2 items, 10 points). The maximum score is 70 points.The higher the score, the greater the cognitive impairment.This is the primary outcome measure most frequently used in clinical trials with drugs.

Secondary Outcome Measures

Global cognitive performance
Global cognitive performance is measured with Test Barcelona TBR-B neuropsychological battery (abreviated version).The ADAS-COG wich is focused on the most devastated areas by Alzheimer's disease, will be complemented by the TBA-B, which has been developed in our environment, makes possible a more global assessment, and also presents adequate psychometric properties.

Full Information

First Posted
July 18, 2014
Last Updated
July 18, 2014
Sponsor
Basque Health Service
search

1. Study Identification

Unique Protocol Identification Number
NCT02195596
Brief Title
Effects of Exercise on Cognitive Performance of Patients With Alzheimer-type Dementia. Pilot Study.
Acronym
EFA-P
Official Title
Effects of Exercise on Cognitive Performance of Patients With Alzheimer-type Dementia. Pilot Study.
Study Type
Interventional

2. Study Status

Record Verification Date
July 2014
Overall Recruitment Status
Unknown status
Study Start Date
April 2013 (undefined)
Primary Completion Date
January 2015 (Anticipated)
Study Completion Date
December 2015 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Basque Health Service

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
A program that combines high intensity aerobic exercise (<85% of Heart Rate Reserve) with resistance, progressive and moderate intensity intervals, carried out in primary care, is effective in terms of a smaller increase in respect to the baseline measurement in the total score of the ADAS cognitive section (Alzheimer Disease Assessment Scale-Cognitive section),in the control group that receives an intervention similar to low intensity (30-40% of Heart rate reserve). We Expect a difference of at least 3 points between the means of the increments between the intervention and control group.
Detailed Description
OBJECTIVE: To evaluate an intervention that combines high intensity aerobic exercise with strength (AAAD) on general cognitive performance of patients affected by mild Alzheimer's disease (AD). DESIGN: Randomized clinical trial in two parallel groups: SCOPE: 2 health center of Basque Health Service , in coordination with its reference neurology services. PARTICIPANTS: 80 patients with mild AD. INTERVENTION: Both groups receiving standard drug treatment. The intervention group also receive a supervised EEAA program, while the control group receive a similar intervention at low intensity. Patients are followed up over 1 year. Three blind measurements are made repeatedly : baseline, at 6 and 12 months. MEASUREMENTS: The primary outcome measure is change in cognitive performance that is measured in a blinded way with the cognitive section of the ADAS scale (Alzheimer's Disease Assessment Scale) at 0, 6 and 12.Secondary Outcomes: Global cognitive performance (Neuropsychological battery TBR-B),neuropsychiatric symptoms (NPI), ADL (Blessed),functional capacity (Test of 6-minute walk), cardiorespiratory Test, muscular strength (hand dynamometer and trunk); PREDICTORS AND CONFOUNDING VARIABLES: baseline cognitive performance, previous physical activity, medication, age, sex, APOE, schooling and cognitive reserve. ANALYSIS: We compared the two groups in terms of observed mean changes from baseline in ADAS measurement and other variables, intention to treat, using longitudinal mixed effects models for repeated measures at 6 and 12 months.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Alzheimer Disease
Keywords
Alzheimer disease, exercise, cognition

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Investigator
Allocation
Randomized
Enrollment
80 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
High intensity aerobic exercise+strength
Arm Type
Experimental
Arm Description
The program consist in a "Continuous High aerobic exercise and moderate intensity intervals" (ShoshanaB et al, 2012) combined with "muscular strength exercises and joint mobility". Patients come three times a week for six months to the primary health center. A fitness expert nurse is responsible for monitoring the performance and adapt to the physical condition of the patient.Each exercise session consists of warming up time period, period of work and back to calm. Exercise intensity during the work period increases progressively as the program progresses. Aerobic exercise is performed on a cycle ergometer or treadmill.Muscle strength exercises and joint mobility are performed with dumbbells and ankle weights adapted to each patient.
Arm Title
Low intensity aerobic exercise+strength
Arm Type
Active Comparator
Arm Description
The control group performed an exercise program similar to intervention but at low intensity that is below 35 or 40% of heart rate reserve (HRR).
Intervention Type
Other
Intervention Name(s)
High intensity aerobic exercise+strength
Intervention Description
The program consist in a "Continuous High aerobic exercise and moderate intensity intervals" (ShoshanaB et al, 2012) combined with "muscular strength exercises and joint mobility". Patients come three times a week for six months to the primary health center and will be supervised by an expert nurse.
Intervention Type
Other
Intervention Name(s)
Low intensity aerobic exercise+strength
Intervention Description
Low intensity aerobic exercise+strength program is similar to the other intervention but differs in the intensity of the exercise as it works with intensities below 40% of heart rate reserve. --------------------------------------------------------------------------------
Primary Outcome Measure Information:
Title
Change in cognitive performance that is measured in a blinded way with the cognitive section of the ADAS scale (Alzheimer's Disease Assessment Scale) at 0, 6 and 12
Description
Cognitive performance is measured in a blinded way with the cognitive section of the ADAS scale (Alzheimer's Disease Assessment Scale) at 0, 6 and 12. ADAS is an instrument designed to assess the severity of cognitive disorders (ADAS-Cog) and noncognitive (ADAS-cog) in patients with Alzheimer-type dementia (ATD). The ADAS-Cog, that we use, consists of 11 items that assess mainly memory (3 items, 27 points), orientation (1 item, 8 points), language (5 items, 25 points) and praxis (2 items, 10 points). The maximum score is 70 points.The higher the score, the greater the cognitive impairment.This is the primary outcome measure most frequently used in clinical trials with drugs.
Time Frame
0, 6 and 12 months
Secondary Outcome Measure Information:
Title
Global cognitive performance
Description
Global cognitive performance is measured with Test Barcelona TBR-B neuropsychological battery (abreviated version).The ADAS-COG wich is focused on the most devastated areas by Alzheimer's disease, will be complemented by the TBA-B, which has been developed in our environment, makes possible a more global assessment, and also presents adequate psychometric properties.
Time Frame
0, 6 and 12 months
Other Pre-specified Outcome Measures:
Title
neuropsychiatric symptoms and psychopathology
Description
NPI will be employed to asses treatment related behavioral changes and the presence of psychopathology in patients receiving exercise
Time Frame
0, 6 and 12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
55 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Subjects aged between 55 and 85 who meet, at the time of entry into the study, clinical criteria compatible with probable AD according to the criteria of the National Institute on Aging and the Alzheimer's Association, under mild or DCL-Alzheimers (Folstein MMSE> 19/20, GDS 3-4), diagnosis will be performed by specialist neurologists according to standard practice. Patients should be able to perform physical activity on a cycle ergometer or treadmill and also must exist a caregiver who agrees to accompany him to the physical exercise sessions. - Exclusion Criteria: Central nervous system disease history with the possibility of neuropsychological impairment (stroke, epilepsy, meningitis, severe head trauma). History of alcohol and drug abuse. Hachinski Ischemic Scale ≥ 7. Major depression diagnosed(CIE-10). History of severe psychiatric disease. Predictable changes in medication that may affect cognitive performance. Visual or auditory perceptual disorders that limit neuropsychological assessment. Unstable heart disease, severe behavioral problems that make impossible the intervention, or any condition judged by the investigator that advises against the intervention. -
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
GONZALO GRANDES ODRIOZOLA, PHD
Phone
0034946006637
Email
gonzalo.grandesodriozola@osakidetza.net
First Name & Middle Initial & Last Name or Official Title & Degree
MAITE ESPINOSACIFUENTES, MD
Phone
0034946006637
Email
maite.espinosacifuentes@osakidetza.net
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
ANA DOSIO REVENGA, PHD
Organizational Affiliation
Osakidetza
Official's Role
Principal Investigator
Facility Information:
Facility Name
Galdakao Hospital/Galdakao C.S.
City
Galdakao
State/Province
Bilbao
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Mª ANGELES GOMEZ BELDARRAIN, PHD
Phone
34 94 400 7234
Email
MARIAANGELES.GOMEZBELDARRAIN@osakidetza.net
First Name & Middle Initial & Last Name & Degree
JAVIER RUIZ OJEDA, PHD
Phone
34 94 400 7234
Email
JAVIER.RUIZOJEDA@OSAKIDETZA.NET
First Name & Middle Initial & Last Name & Degree
Mª SOLEDAD ARIETALEANIZBEASKOA SARABIA
First Name & Middle Initial & Last Name & Degree
ANA DOSIO REVENGA
First Name & Middle Initial & Last Name & Degree
AGUSTÍN SASTRE PEREZ
Facility Name
Basauri C.S.
City
Basauri
State/Province
Bizkaia
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
NEREA FONCEA BETI, PHD
Phone
03494 4007234
Email
NEREA.FONCEABETI@osakidetza.net
First Name & Middle Initial & Last Name & Degree
VERÓNICA ARCE ARANA
First Name & Middle Initial & Last Name & Degree
ANGEL FERNÁNDEZ MARTÍNEZ
First Name & Middle Initial & Last Name & Degree
MARÍA CARBALLUDE PRIETO
First Name & Middle Initial & Last Name & Degree
IZASKUN GAMBOA AURTENECHE
Facility Name
Hospital Universitario de Basurto
City
Bilbao
State/Province
Bizkaia
Country
Spain
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
JUAN Mª UTERGA VALIENTE, PHD
Phone
944006074
Email
JUANMARIA.UTERGAVALIENTE@osakidetza.net
First Name & Middle Initial & Last Name & Degree
MAITE ESPINOSA CIFUENTES, MD

12. IPD Sharing Statement

Learn more about this trial

Effects of Exercise on Cognitive Performance of Patients With Alzheimer-type Dementia. Pilot Study.

We'll reach out to this number within 24 hrs